Wedbush Downgrades Artiva Biotherapeutics to Neutral, Lowers Price Target to $4
Benzinga Newsdesk 6 days ago
Analyst RatingsNewsDowngradesPrice Target
Wedbush analyst David Nierengarten downgrades Artiva Biotherapeutics (NASDAQ:ARTV) from Outperform to Neutral and lowers the price target from $40 to $4.
Wedbush analyst David Nierengarten downgrades Artiva Biotherapeutics (NASDAQ:ARTV) from Outperform to Neutral and lowers the price target from $40 to $4.